BURNABY, BRITISH COLUMBIA--(Marketwire - Dec. 6, 2011) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD) ("LED" or the "Company"), a leading medical diagnostics company, today announced its financial results for the three and nine months ended September 30, 2011. For the nine months ended September 30, 2011, the Company increased revenue by 275% over the prior year to $5.1 million compared to approximately $1.4 million in the same period of the prior year. Results are reported in Canadian dollars and in accordance with International Financial Reporting Standards ("IFRS"). The Company's results are presented in comparison to the three months ended June 30, 2011 and September 30, 2010, respectively, also in accordance with IFRS.

"We are very proud of having developed one of the world's leading adjunctive cancer screening tool, the VELscope Vx, which was successfully launched at the beginning of this year in the North American market. The VELscope Vx is the newest handheld version of our patented VELscope technology and is the culmination of years of research and development and earlier sales efforts," said Peter Whitehead, President and Chief Executive Office. Whitehead continued, "This year's launch of the VELscope Vx has resulted in revenues of $5.1 million for the nine months ended September 30, 2011, a significant increase of 275% over the prior year's revenues of $1.4 million. In addition, our consumables sales have increased to $930,437 from $436,348 over this period, an increase of 113%. Partnering with industry leader Henry Schein, we have greatly expanded our sales and distribution reach and continue to brand our flagship product while we push for international expansion."

"For the third quarter ended September 30, 2011, the Company reported revenues of approximately $555,915 as compared to approximately $270,657 for the third quarter of 2010, an increase of 51% over the prior year period. Revenues were lower this quarter from the second and first quarters of 2011 of $1.8 million and $3.0 million, respectively, which was attributable to the seasonality of the industry and the traditionally slow months of the summer. Based on orders booked to date, the Company expects an increase in revenues in our fourth quarter and strong annual revenue growth over prior years," stated Mr. Whitehead.

Total operating expenses, excluding other operating expenses, for the three months ended September 30, 2011 were 9% lower than the preceding three months ended June 30, 2011 and 79% higher than the comparable three months ended September 30, 2010. Earnings before other operating expenses, finance income and foreign exchange gain (loss) ("EBITDA") for the three months ended September 30, 2011 was ($984,446) compared to ($684,268) for the previous three months ended June 30, 2011 and ($555,882) for the comparable three months ended September 30, 2010. Cash and cash equivalents were approximately $219,411 with net working capital of approximately ($639,011) as of September 30, 2011, compared to cash and cash equivalents of approximately $269,010 with negative net working capital of approximately ($1.0 million as of December 31, 2010.

On November 21, 2011, the Company amalgamated with Searchlight Capital Corporation. In connection with the transaction, holders of common shares of Searchlight received one common share of the Company for every 1.66666 common shares of Searchlight held. Concurrent with the completion of this arrangement, the Company completed a non-brokered private placement unit offering in the amount of $1.1 million with each unit consisting of one common share of the Company and one-half of a share purchase warrant where each whole warrant is exercisable into one common share of the Company at an exercise price of $1.00 for a period of 18 months. The private placement units are subjected to a four month hold period.

The new accounting policies under IFRS have been consistently applied to all of the periods presented in this news release. Further details on the conversion to IFRS are provided in Management's Discussion and Analysis and in the notes to the Company's unaudited condensed consolidated financial statements as at and for the three and nine months ended September 30, 2011.

The Audit Committee of the Company has reviewed the contents of this news release.

Forward-Looking Statements

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to: the need to develop products to meet the Company's customer's requirements; the possibility of development or deployment difficulties or delays; the dependence on the Company's customer's satisfaction; the timing of entering into significant contracts; customers' continued commitment to the deployment of the Company's solutions; the performance of the global economy and growth in sales; market acceptance of the Company's products; the success of certain business combinations engaged in by the Company or by its competitors; possible disruptive effects of organizational or personnel changes; technological change, new products and standards; risks related to international expansion; concentration of sales; international operations and sales; dependence upon key personnel and hiring; reliance on a limited number of suppliers; industry growth; competition; intellectual property; product defects and product liability; currency exchange rate risk; and other factors described in the Company's reports filed on SEDAR, including its financial report for the three months ended September 30, 2011. This list is not exhaustive of the factors that may affect the Company's forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward- looking information, whether as a result of new information, future events or otherwise, except as required by law.

About LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc. ("LED") develops and commercializes medical devices based on its proprietary imaging platform to aid in the detection and treatment of disease in human tissues. The Company has developed a device it now markets under the trade name VELscope®. The device is used in the dental industry to help identify oral soft tissue abnormalities including those which may be cancerous or precancerous and also to help define appropriate margins for surgical excision. The VELscope® system consists of a combined light source and handpiece and accompanying consumables used for each exam. The Company's head office is located at 235 - 5589 Byrne Road, Burnaby, British Columbia, Canada, V5J 3J1 LED is publicly traded (TSX VENTURE:LMD). For more information, call (604) 434- 4614, or visit [ www.VELscope.com ].